Published in Best Pract Res Clin Gastroenterol on May 09, 2015
Celiac disease is associated with reduced bone mineral density and increased FRAX scores in the US National Health and Nutrition Examination Survey. Osteoporos Int (2016) 0.76
Immunopathogenesis and therapeutic approaches in pediatric celiac disease. Expert Rev Clin Immunol (2016) 0.75
Implementation of the agmatine-controlled expression system for inducible gene expression in Lactococcus lactis. Microb Cell Fact (2015) 0.75
Challenges in the celiac disease diagnosis; Prague consensus. Gastroenterol Hepatol Bed Bench (2017) 0.75
Celiac disease: From pathophysiology to treatment. World J Gastrointest Pathophysiol (2017) 0.75
Circos: an information aesthetic for comparative genomics. Genome Res (2009) 40.02
Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci. Nat Genet (2010) 17.38
Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature (2012) 16.13
Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med (2004) 14.53
The gut microbiota shapes intestinal immune responses during health and disease. Nat Rev Immunol (2009) 13.87
Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature (2011) 13.23
B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med (2008) 12.90
A genome-wide association study for celiac disease identifies risk variants in the region harboring IL2 and IL21. Nat Genet (2007) 8.50
Structural basis for gluten intolerance in celiac sprue. Science (2002) 8.16
Meta-analysis of genome-wide association study data identifies additional type 1 diabetes risk loci. Nat Genet (2008) 7.71
Shared and distinct genetic variants in type 1 diabetes and celiac disease. N Engl J Med (2008) 7.66
Newly identified genetic risk variants for celiac disease related to the immune response. Nat Genet (2008) 7.63
Identification of tissue transglutaminase as the autoantigen of celiac disease. Nat Med (1997) 7.42
Multiple common variants for celiac disease influencing immune gene expression. Nat Genet (2010) 6.90
Dense genotyping identifies and localizes multiple common and rare variant association signals in celiac disease. Nat Genet (2011) 6.36
Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med (2013) 4.75
Coordinated induction by IL15 of a TCR-independent NKG2D signaling pathway converts CTL into lymphokine-activated killer cells in celiac disease. Immunity (2004) 4.36
Vedolizumab as induction and maintenance therapy for Crohn's disease. N Engl J Med (2013) 3.98
A direct role for NKG2D/MICA interaction in villous atrophy during celiac disease. Immunity (2004) 3.76
Increased prevalence and mortality in undiagnosed celiac disease. Gastroenterology (2009) 3.73
Crohn's disease. Lancet (2002) 3.53
Identification of IL6R and chromosome 11q13.5 as risk loci for asthma. Lancet (2011) 3.03
Zonulin, a newly discovered modulator of intestinal permeability, and its expression in coeliac disease. Lancet (2000) 2.82
Trichuris suis ova therapy for allergic rhinitis: a randomized, double-blind, placebo-controlled clinical trial. J Allergy Clin Immunol (2009) 2.74
Myosin IXB variant increases the risk of celiac disease and points toward a primary intestinal barrier defect. Nat Genet (2005) 2.71
Evidence for polygenic susceptibility to multiple sclerosis--the shape of things to come. Am J Hum Genet (2010) 2.64
Fucosyltransferase 2 (FUT2) non-secretor status is associated with Crohn's disease. Hum Mol Genet (2010) 2.51
Larazotide acetate in patients with coeliac disease undergoing a gluten challenge: a randomised placebo-controlled study. Aliment Pharmacol Ther (2012) 2.46
Effect of T-cell peptides derived from Fel d 1 on allergic reactions and cytokine production in patients sensitive to cats: a randomised controlled trial. Lancet (2002) 2.38
BACH2 represses effector programs to stabilize T(reg)-mediated immune homeostasis. Nature (2013) 2.36
Altered duodenal microbiota composition in celiac disease patients suffering from persistent symptoms on a long-term gluten-free diet. Am J Gastroenterol (2014) 2.34
Structural basis for HLA-DQ2-mediated presentation of gluten epitopes in celiac disease. Proc Natl Acad Sci U S A (2004) 2.33
Treatment of patients with new onset Type 1 diabetes with a single course of anti-CD3 mAb Teplizumab preserves insulin production for up to 5 years. Clin Immunol (2009) 2.30
Gluten specific, HLA-DQ restricted T cells from coeliac mucosa produce cytokines with Th1 or Th0 profile dominated by interferon gamma. Gut (1995) 2.29
Gene disruption of tissue transglutaminase. Mol Cell Biol (2001) 2.15
Reprogramming of CTLs into natural killer-like cells in celiac disease. J Exp Med (2006) 2.03
Themis, a T cell-specific protein important for late thymocyte development. Nat Immunol (2009) 2.00
Chemistry and biology of dihydroisoxazole derivatives: selective inhibitors of human transglutaminase 2. Chem Biol (2005) 2.00
Diagnostic testing for celiac disease among patients with abdominal symptoms: a systematic review. JAMA (2010) 1.99
Gliadin induces an increase in intestinal permeability and zonulin release by binding to the chemokine receptor CXCR3. Gastroenterology (2008) 1.98
Intestinal digestive resistance of immunodominant gliadin peptides. Am J Physiol Gastrointest Liver Physiol (2002) 1.87
Targeted inactivation of Gh/tissue transglutaminase II. J Biol Chem (2001) 1.86
Early effects of gliadin on enterocyte intracellular signalling involved in intestinal barrier function. Gut (2003) 1.84
Genome-wide association analyses identify 13 new susceptibility loci for generalized vitiligo. Nat Genet (2012) 1.81
Glutenase ALV003 attenuates gluten-induced mucosal injury in patients with celiac disease. Gastroenterology (2014) 1.81
Gliadin, zonulin and gut permeability: Effects on celiac and non-celiac intestinal mucosa and intestinal cell lines. Scand J Gastroenterol (2006) 1.81
Malignant lymphomas in coeliac disease: evidence of increased risks for lymphoma types other than enteropathy-type T cell lymphoma. Gut (2005) 1.75
Efficient degradation of gluten by a prolyl endoprotease in a gastrointestinal model: implications for coeliac disease. Gut (2007) 1.75
Identification of human zonulin, a physiological modulator of tight junctions, as prehaptoglobin-2. Proc Natl Acad Sci U S A (2009) 1.67
Receptor tyrosine phosphatase R-PTP-kappa mediates homophilic binding. Mol Cell Biol (1994) 1.64
Comparative biochemical analysis of three bacterial prolyl endopeptidases: implications for coeliac sprue. Biochem J (2004) 1.63
Highly efficient gluten degradation with a newly identified prolyl endoprotease: implications for celiac disease. Am J Physiol Gastrointest Liver Physiol (2006) 1.62
Differentiation and homing of IgA-secreting cells. Mucosal Immunol (2008) 1.61
Exploratory, randomized, double-blind, placebo-controlled study on the effects of Bifidobacterium infantis natren life start strain super strain in active celiac disease. J Clin Gastroenterol (2013) 1.60
Autoantibodies in coeliac disease: tissue transglutaminase--guilt by association? Gut (1997) 1.60
Steady-state generation of mucosal IgA+ plasmablasts is not abrogated by B-cell depletion therapy with rituximab. Blood (2010) 1.57
Factor XIII: a coagulation factor with multiple plasmatic and cellular functions. Physiol Rev (2011) 1.56
Systematic review: worldwide variation in the frequency of coeliac disease and changes over time. Aliment Pharmacol Ther (2013) 1.50
The safety, tolerance, pharmacokinetic and pharmacodynamic effects of single doses of AT-1001 in coeliac disease subjects: a proof of concept study. Aliment Pharmacol Ther (2007) 1.49
Secretor genotype (FUT2 gene) is strongly associated with the composition of Bifidobacteria in the human intestine. PLoS One (2011) 1.49
A proof of concept study establishing Necator americanus in Crohn's patients and reservoir donors. Gut (2006) 1.48
Effect of addition of short course of prednisolone to gluten-free diet on mucosal epithelial cell regeneration and apoptosis in celiac disease: a pilot randomized controlled trial. Dig Dis Sci (2012) 1.47
A structural and immunological basis for the role of human leukocyte antigen DQ8 in celiac disease. Immunity (2007) 1.46
Secretory IgA mediates retrotranscytosis of intact gliadin peptides via the transferrin receptor in celiac disease. J Exp Med (2007) 1.43
Characterization of CCX282-B, an orally bioavailable antagonist of the CCR9 chemokine receptor, for treatment of inflammatory bowel disease. J Pharmacol Exp Ther (2010) 1.40
Transglutaminase-1 gene mutations in autosomal recessive congenital ichthyosis: summary of mutations (including 23 novel) and modeling of TGase-1. Hum Mutat (2009) 1.39
Effect of pretreatment of food gluten with prolyl endopeptidase on gluten-induced malabsorption in celiac sprue. Clin Gastroenterol Hepatol (2005) 1.38
Structure-activity relationship study of novel tissue transglutaminase inhibitors. Bioorg Med Chem Lett (2005) 1.38
Celiac disease genetics: current concepts and practical applications. Clin Gastroenterol Hepatol (2005) 1.37
Increased risk for non-Hodgkin lymphoma in individuals with celiac disease and a potential familial association. Gastroenterology (2008) 1.36
Transforming growth factor {beta} (TGF-{beta})-Smad target gene protein tyrosine phosphatase receptor type kappa is required for TGF-{beta} function. Mol Cell Biol (2005) 1.36
Celiac disease. Annu Rev Med (2006) 1.35
Malignancies and mortality in patients with coeliac disease and dermatitis herpetiformis: 30-year population-based study. Dig Liver Dis (2006) 1.35
Effect of hookworm infection on wheat challenge in celiac disease--a randomised double-blinded placebo controlled trial. PLoS One (2011) 1.30
Antibody-mediated blockade of IL-15 reverses the autoimmune intestinal damage in transgenic mice that overexpress IL-15 in enterocytes. Proc Natl Acad Sci U S A (2009) 1.28
IL-15 triggers an antiapoptotic pathway in human intraepithelial lymphocytes that is a potential new target in celiac disease-associated inflammation and lymphomagenesis. J Clin Invest (2010) 1.28
The current future understanding of inflammatory bowel disease. Best Pract Res Clin Gastroenterol (2002) 1.28
Successful infliximab treatment for steroid-refractory celiac disease: a case report. Gastroenterology (2002) 1.26
Zonula occludens toxin structure-function analysis. Identification of the fragment biologically active on tight junctions and of the zonulin receptor binding domain. J Biol Chem (2001) 1.25
T cell epitope immunotherapy induces a CD4+ T cell population with regulatory activity. PLoS Med (2005) 1.24
Budesonide in the treatment of refractory celiac disease. Am J Gastroenterol (2007) 1.23
FUT2 nonsecretor status links type 1 diabetes susceptibility and resistance to infection. Diabetes (2011) 1.22
The effects of ALV003 pre-digestion of gluten on immune response and symptoms in celiac disease in vivo. Clin Immunol (2009) 1.22
Safety, tolerability, and activity of ALV003: results from two phase 1 single, escalating-dose clinical trials. Dig Dis Sci (2011) 1.21
Abnormal B-cell responses to chemokines, disturbed plasma cell localization, and distorted immune tissue architecture in Rgs1-/- mice. Mol Cell Biol (2004) 1.20
VSL#3 probiotic preparation has the capacity to hydrolyze gliadin polypeptides responsible for Celiac Sprue. Biochim Biophys Acta (2005) 1.19
Prolyl endopeptidases. Cell Mol Life Sci (2007) 1.18
Novel therapies for coeliac disease. J Intern Med (2011) 1.17
Themis sets the signal threshold for positive and negative selection in T-cell development. Nature (2013) 1.17
A non-human primate model for gluten sensitivity. PLoS One (2008) 1.17
Heterologous expression, purification, refolding, and structural-functional characterization of EP-B2, a self-activating barley cysteine endoprotease. Chem Biol (2006) 1.17
Fontolizumab in moderate to severe Crohn's disease: a phase 2, randomized, double-blind, placebo-controlled, multiple-dose study. Inflamm Bowel Dis (2010) 1.15
Consumption of gluten with gluten-degrading enzyme by celiac patients: a pilot-study. World J Gastroenterol (2013) 1.14
A distinctive 'microbial signature' in celiac pediatric patients. BMC Microbiol (2010) 1.14
Polymeric binders suppress gliadin-induced toxicity in the intestinal epithelium. Gastroenterology (2008) 1.12
A deletion mutation of the protein tyrosine phosphatase kappa (Ptprk) gene is responsible for T-helper immunodeficiency (thid) in the LEC rat. Mamm Genome (2007) 1.12
Regulator of G protein signaling 1 (RGS1) markedly impairs Gi alpha signaling responses of B lymphocytes. J Immunol (2000) 1.11
A food-grade enzyme preparation with modest gluten detoxification properties. PLoS One (2009) 1.10